Login +0086-27-65522453 [email protected]

Dactolisib (BEZ235, NVP-BEZ235) Catalog No : 52619

Chemical Information

Product NameDactolisib (BEZ235, NVP-BEZ235)
SynonymsDactolisib, BEZ235, NVP-BEZ235,NVPBEZ235
Molecular FormulaC30H23N5O 
Molecular Weight469.54 
SmileCC(C)(C#N)n1c2c3cc(ccc3ncc2n(c1=O)C)c4cc5ccccc5nc4
InChiKeyKGAAOKXUCALAPY-UHFFFAOYSA-N
InChiInChI=1S/C24H19N5O/c1-24(2,14-25)29-22-18-11-15(17-10-16-6-4-5-7-19(16)26-12-17)8-9-20(18)27-13-21(22)28(3)23(29)30/h4-13H,1-3H3
Cas915019-65-7
MDLMFCD18785767

Technical Data

AppearanceSolid powder
Purity98% 
SolubilitySoluble in DMSO, not in water
StorageDry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Shipping ConditionShipped under ambient temperature as non-hazardous chemical. 
Quality control

Description

From Wikipedia, the free encyclopedia

Dactolisib (codenamed NVP-BEZ235 and BEZ-235) is an imidazoquinoline derivative acting as a PI3K inhibitor.[1] It also inhibits mTOR. It is being investigated as a possible cancer treatment.

It has been shown to be toxic to Waldenström's macroglobulinemia cells.

It was the first PI3K inhibitor to enter clinical trials, in 2006.

A phase IB/II clinical trial for locally advanced or metastatic HER2 negative breast cancer has completed.

A phase II clinical trial for advanced pancreatic neuroendocrine tumors (pNET) has reported results.

Chemical Structure

52619 - Dactolisib (BEZ235, NVP-BEZ235) | CAS 915019-65-7

Package

SizePrice
Login to get price

Quick Order

Change

Contact Us